Alkeus Pharmaceuticals, a Cambridge, MA-based biopharmaceutical company that specializes in eye diseases, has raised $150 million in Series B funding.
The round was led by Bain Capital Life Sciences, with additional participation by TCGX, Wellington Management and Sofinnova Investments. Joshua Boger, Ph.D., a biotech industry pioneer and the founder of Vertex Pharmaceuticals, joined Alkeus as Executive Chairman.
The company intends to use the funds for the registration and launch of gildeuretinol (ALK-001), a potential disease-modifying, precision medicine for the treatment of Stargardt disease, a genetic cause of blindness in children and young adults.
Led by Leonide Saad, Ph.D., CEO and President, and Joshua Boger, Ph.D., Executive Chairman, Alkeus Pharmaceuticals is a biopharmaceutical company focused on developing therapies for serious diseases of the eye with high unmet need. Its lead candidate, gildeuretinol (ALK-001), is currently being evaluated in clinical trials for the treatment of Stargardt disease and for geographic atrophy secondary to dry age-related macular degeneration (AMD).
FinSMEs
07/06/2023